Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia.
Krystal AD, Pizzagalli DA, Smoski M, Mathew SJ, Nurnberger J Jr, Lisanby SH, Iosifescu D, Murrough JW, Yang H, Weiner RD, Calabrese JR, Sanacora G, Hermes G, Keefe RSE, Song A, Goodman W, Szabo ST, Whitton AE, Gao K, Potter WZ. Krystal AD, et al. Among authors: keefe rse. Nat Med. 2020 May;26(5):760-768. doi: 10.1038/s41591-020-0806-7. Epub 2020 Mar 30. Nat Med. 2020. PMID: 32231295 Free PMC article. Clinical Trial.
The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development.
Krystal AD, Pizzagalli DA, Mathew SJ, Sanacora G, Keefe R, Song A, Calabrese J, Goddard A, Goodman W, Lisanby SH, Smoski M, Weiner R, Iosifescu D, Nurnberger J Jr, Szabo S, Murrough J, Shekhar A, Potter W. Krystal AD, et al. Nat Rev Drug Discov. 2018 Dec 28;18(1):82-84. doi: 10.1038/nrd.2018.222. Nat Rev Drug Discov. 2018. PMID: 30591715 Free PMC article. No abstract available.
Can IQ moderate the response to cognitive remediation in people with schizophrenia?
Seccomandi B, Agbedjro D, Bell M, Keefe RSE, Keshavan M, Galderisi S, Fiszdon J, Mucci A, Cavallaro R, Bechi M, Ojeda N, Peña J, Wykes T, Cella M. Seccomandi B, et al. Among authors: keefe rse. J Psychiatr Res. 2021 Jan;133:38-45. doi: 10.1016/j.jpsychires.2020.12.013. Epub 2020 Dec 4. J Psychiatr Res. 2021. PMID: 33307353
Cognitive impairment in schizophrenia.
Keefe RS, Harvey PD. Keefe RS, et al. Handb Exp Pharmacol. 2012;(213):11-37. doi: 10.1007/978-3-642-25758-2_2. Handb Exp Pharmacol. 2012. PMID: 23027411 Review.
Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.
Marx CE, Lee J, Subramaniam M, Rapisarda A, Bautista DC, Chan E, Kilts JD, Buchanan RW, Wai EP, Verma S, Sim K, Hariram J, Jacob R, Keefe RS, Chong SA. Marx CE, et al. Psychopharmacology (Berl). 2014 Sep;231(17):3647-62. doi: 10.1007/s00213-014-3673-4. Epub 2014 Jul 17. Psychopharmacology (Berl). 2014. PMID: 25030803 Clinical Trial.
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia.
Marx CE, Keefe RS, Buchanan RW, Hamer RM, Kilts JD, Bradford DW, Strauss JL, Naylor JC, Payne VM, Lieberman JA, Savitz AJ, Leimone LA, Dunn L, Porcu P, Morrow AL, Shampine LJ. Marx CE, et al. Neuropsychopharmacology. 2009 Jul;34(8):1885-903. doi: 10.1038/npp.2009.26. Epub 2009 Apr 1. Neuropsychopharmacology. 2009. PMID: 19339966 Free PMC article. Clinical Trial.
325 results